A Fresh Look at the Health-Wealth Correlation: A Case Study of European Countries

from Health Economics at http://bit.ly/2OOhVuw on October 14, 2019 at 07:08PM This paper contributes to the development-health literature by studying the correlation between development measures (see below) and health measures – one subjective (‘self-assessed-health-status’), and the other one objective (the individual’s ‘number of chronic diseases’). Correlations are examined for 29 European countries, using the SHARE […]

How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs

from Health Economics at http://bit.ly/31dyjrg on October 14, 2019 at 07:08PM Prior work considers effects of prescribing restrictions on opioid use but not upstream implications for pharmaceutical marketing activities, despite the inordinate role many believe marketing played in the crisis. Our study proposes a stylized model of pharmaceutical payments and investigates the impact of Mandatory […]

Drug Diffusion Through Peer Networks: The Influence of Industry Payments

from Health Economics at http://bit.ly/35v2KfH on October 14, 2019 at 07:08PM Pharmaceutical companies’ marketing efforts primarily target physicians, often through individual detailing that entails monetary or in-kind transfers. We study how peer influence broadens these payments’ reach beyond the directly paid physicians. Combining Medicare prescriptions and Open Payments data for anticoagulant drugs, we document that […]

Market definition in the pharmaceutical industry: a case of drugs hopping antitrust markets?

from Health Economics at http://bit.ly/2oFuY6Q on October 14, 2019 at 07:08PM Delineating the boundaries of the relevant market plays a central role in the conduct of competition policy. In this paper, we focus on market definition in the pharmaceutical industry, where the introduction of generics represents a significant competitive shock for the molecule experiencing Loss […]